Nasdaq · CIK 0001133416
GALT GALECTIN THERAPEUTICS INC
Insider trading from SEC Form 4. Last filing Mar 17, 2026. Close $3.94 on Oct 9, 2026, +89% from the 52-week low and -39% from the high.
GALECTIN THERAPEUTICS INC (GALT) has 73 SEC Form 4 filings on file from 14 insiders, the latest filed on Mar 17, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
43 open-market trades have been scored at GALT. The newest: Kary Eldred (director) bought $810 of stock on Feb 6, 2026, filed Feb 9, 2026, scored 23 (weak). The largest of the 43 shown: Harold H. Shlevin (director) sold $1.1M on Dec 8, 2025, scored 40 (moderate), under a 10b5-1 plan. 3 insiders sold within 14 days of each other around Jan 2, 2026.
GALT closed at $3.94 on Oct 9, 2026, 89% above its 52-week low and 39% below its 52-week high.
5 Form 144 notices of planned sales are on file, the latest filed Sep 12, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
GALTOct 9, 2026 · close 3.94
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at GALECTIN THERAPEUTICS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Kary Eldred director buy | $810 300 shares | +0% | +130% from low-57% from high | |
| 35Weak | Jack W Callicutt Chief Financial Officer sell | $233k 60,000 shares | -89% | +268% from low-38% from high | |
| 28Weak | Khurram Jamil Chief Medical Officer sell | $232k 60,000 shares | -100% | +268% from low-38% from high | |
| 19Weak | Joel Lewis President and CEO sell | $321k 84,000 shares | -9% | +268% from low-38% from high | |
| 21Weak | Khurram Jamil Chief Medical Officer sell | $33k 8,125 shares | -100% | +278% from low-36% from high | |
| 16Weak | Kary Eldred director buy | $2,611 700 shares | +1% | +375% from low-39% from high | |
| 31Weak | Kary Eldred director buy | $2,611 700 shares | +1% | +375% from low-39% from high | |
| 19Weak | Kevin D Freeman director buy | $20k 5,500 shares | +11% | +375% from low-39% from high | |
| 19Weak | Kevin D Freeman director buy | $20k 5,500 shares | +11% | +375% from low-39% from high | |
| 34Weak | Kevin D Freeman director buy | $20k 5,500 shares | +11% | +375% from low-39% from high | |
| 26Weak | Harold H. Shlevin director sell | $172k 24,499 shares | -79% | +670% from low-1% from high | |
| 26Weak | Khurram Jamil Chief Medical Officer sell | $137k 19,442 shares | -434% | +670% from low-1% from high | |
| 12Weak | Joel Lewis President and CEO sell | $55k 7,829 shares | -1% | +670% from low-1% from high | |
| 39Weak | 10X Fund, L.P. owner sell | $204k 30,681 shares | -1% | +638% from low-5% from high | |
| 27Weak | Harold H. Shlevin director sell | $177k 28,210 shares | -91% | +644% from low-1% from high | |
| 40Moderate | Harold H. Shlevin director sell | $1.1M 175,790 shares | -1156% | +617% from low-4% from high | |
| 44Moderate | 10X Fund, L.P. owner sell | $921k 162,069 shares | -3% | +550% from low-12% from high | |
| 43Moderate | 10X Fund, L.P. owner sell | $852k 150,000 shares | -3% | +550% from low-12% from high | |
| 40Moderate | Jack W Callicutt Chief Financial Officer sell | $479k 77,920 shares | -453% | +614% from low0% from high | |
| 16Weak | Joel Lewis President and CEO sell | $136k 22,463 shares | -3% | +614% from low0% from high | |
| 35Weak | Khurram Jamil Chief Medical Officer sell | $663k 121,117 shares | -460% | +558% from low-8% from high | |
| 39Weak | 10X Fund, L.P. owner sell | $210k 40,000 shares | -1% | +555% from low-8% from high | |
| 27Weak | Jack W Callicutt Chief Financial Officer sell | $32k 5,291 shares | -56% | +519% from low-13% from high | |
| 5Weak | Joel Lewis President and CEO sell | $11k 1,867 shares | -0% | +519% from low-13% from high | |
| 2Weak | Jack W Callicutt Chief Financial Officer sell | $3,600 600 shares | -8% | +570% from low-6% from high | |
| 5Weak | Joel Lewis President and CEO sell | $1,200 200 shares | -0% | +570% from low-6% from high | |
| 34Weak | Jack W Callicutt Chief Financial Officer sell | $197k 32,439 shares | -364% | +614% from low0% from high | |
| 15Weak | Joel Lewis President and CEO sell | $95k 15,720 shares | -2% | +614% from low0% from high | |
| 40Moderate | 10X Fund, L.P. owner sell | $247k 50,000 shares | -1% | +481% from low-18% from high | |
| 22Weak | Jack W Callicutt Chief Financial Officer sell | $56k 8,706 shares | -53% | +539% from low-10% from high | |
| 7Weak | Joel Lewis President and CEO sell | $89k 14,000 shares | -2% | +539% from low-10% from high | |
| 27Weak | Kary Eldred director buy | $2,925 1,000 shares | +2% | +226% from low-17% from high | |
| 26Weak | Kevin D Freeman director buy | $14k 5,000 shares | +11% | +244% from low-12% from high | |
| 40Moderate | Harold H. Shlevin director buy | $7,540 6,500 shares | +75% | - | |
| 28Weak | Jack W Callicutt Chief Financial Officer sell | $35k 40,000 shares | -84% | - | |
| 41Moderate | Kary Eldred director buy | $11k 13,469 shares | +27% | - | |
| 41Moderate | Kevin D Freeman director buy | $8,134 10,000 shares | +29% | - | |
| 36Weak | Richard A. Zordani Jr. director buy | $8,164 10,000 shares | +31% | - | |
| 12Weak | Joel Lewis President and CEO sell | $50k 56,000 shares | -6% | - | |
| 5Weak | Khurram Jamil Chief Medical Officer sell | $12k 13,654 shares | -34% | - | |
| 23Weak | Kary Eldred director buy | $1,300 500 shares | +1% | - | |
| 28Weak | Kevin D Freeman director buy | $3,432 1,300 shares | +4% | - | |
| 34Weak | Kevin D Freeman director buy | $27k 10,000 shares | +35% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 12, 2025 | CALLICUTT JACK W Officer | 141,206 0.22% of outstanding | $909k | Sep 12, 2025 | none |
| Sep 12, 2025 | LEWIS JOEL Officer | 54,250 0.08% of outstanding | $345k | Sep 12, 2025 | none |
| Dec 23, 2024 | CALLICUTT JACK W Officer | 40,000 0.06% of outstanding | $42k | Dec 23, 2024 | none |
| Dec 23, 2024 | LEWIS JOEL Officer | 56,000 0.09% of outstanding | $58k | Dec 23, 2024 | none |
| Dec 23, 2024 | Jamil Khurram Officer | 13,654 0.02% of outstanding | $14k | Dec 23, 2024 | none |
Transactions
The newest 50 of 235 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | Henry Brem director | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Mar 17, 2026 |
| Feb 6, 2026 | Kary Eldred director | POpen-market purchase Common Stock | +300 | $2.70 | $810 | 65,682 | Feb 9, 2026 |
| Jan 16, 2026 | Joel Lewis President and CEO | AGrant or award Stock option (right to buy)derivative | +91,000 | $0.00 | $0 | 91,000 | Jan 22, 2026 |
| Jan 16, 2026 | Richard E Uihlein director, owner | AGrant or award Common Stock | +13,158 | $3.04 | $40k | 10,332,676 | Jan 21, 2026 |
| Jan 16, 2026 | Khurram Jamil Chief Medical Officer | AGrant or award Stock option (right to buy)derivative10b5-1 | +65,000 | $0.00 | $0 | 65,000 | Jan 21, 2026 |
| Jan 16, 2026 | Jack W Callicutt Chief Financial Officer | AGrant or award Stock option (right to buy)derivative10b5-1 | +65,000 | $0.00 | $0 | 65,000 | Jan 21, 2026 |
| Jan 16, 2026 | Kary Eldred director | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 21, 2026 |
| Jan 16, 2026 | Kevin D Freeman director | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 21, 2026 |
| Jan 16, 2026 | Benjamin Carson Sr director | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 21, 2026 |
| Jan 16, 2026 | Gilbert S Omenn director | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 21, 2026 |
| Jan 16, 2026 | Gilbert F Amelio director | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 21, 2026 |
| Jan 16, 2026 | Joel Lewis President and CEO | AGrant or award Stock option (right to buy)derivative10b5-1 | +84,000 | $0.00 | $0 | 65,000 | Jan 21, 2026 |
| Jan 16, 2026 | Richard A. Zordani Jr. director | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 21, 2026 |
| Jan 16, 2026 | Elissa J. Schwartz director | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 21, 2026 |
| Jan 16, 2026 | Harold H. Shlevin director | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 21, 2026 |
| Jan 16, 2026 | Khurram Jamil Chief Medical Officer | AGrant or award Restricted Stock Unitderivative10b5-1 | +100,000 | $0.00 | $0 | 100,000 | Jan 21, 2026 |
| Jan 16, 2026 | Jack W Callicutt Chief Financial Officer | AGrant or award Restricted Stock Unitderivative10b5-1 | +100,000 | $0.00 | $0 | 100,000 | Jan 21, 2026 |
| Jan 16, 2026 | Joel Lewis President and CEO | AGrant or award Restricted Stock Unitderivative10b5-1 | +120,000 | $0.00 | $0 | 100,000 | Jan 21, 2026 |
| Jan 16, 2026 | Richard E Uihlein director, owner | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 21, 2026 |
| Jan 5, 2026 | Joel Lewis President and CEO | Other Common Stock10b5-1 | -56,332 | $3.88 | $219k | 776,260 | Jan 13, 2026 |
| Jan 2, 2026 | Jack W Callicutt Chief Financial Officer | MOption exercise Common Stock10b5-1 | +60,000 | $0.00 | $0 | 67,614 | Jan 6, 2026 |
| Jan 2, 2026 | Khurram Jamil Chief Medical Officer | MOption exercise Common Stock10b5-1 | +60,000 | $0.00 | $0 | 60,000 | Jan 6, 2026 |
| Jan 2, 2026 | Joel Lewis President and CEO | MOption exercise Common Stock10b5-1 | +84,000 | $0.00 | $0 | 916,592 | Jan 6, 2026 |
| Jan 2, 2026 | Joel Lewis President and CEO | SOpen-market sale Common Stock10b5-1 | -18,571 | $4.20 | $78k | 898,021 | Jan 6, 2026 |
| Jan 2, 2026 | Jack W Callicutt Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -13,914 | $4.20 | $58k | 53,700 | Jan 6, 2026 |
| Jan 2, 2026 | Khurram Jamil Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -13,055 | $4.20 | $55k | 46,945 | Jan 6, 2026 |
| Jan 5, 2026 | Jack W Callicutt Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -25,732 | $3.90 | $100k | 27,968 | Jan 6, 2026 |
| Jan 5, 2026 | Khurram Jamil Chief Medical Officer | SOpen-market sale Common stock10b5-1 | -25,499 | $3.90 | $99k | 21,446 | Jan 6, 2026 |
| Jan 5, 2026 | Joel Lewis President and CEO | SOpen-market sale Common Stock10b5-1 | -27,731 | $3.91 | $108k | 870,290 | Jan 6, 2026 |
| Jan 6, 2026 | Jack W Callicutt Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -20,354 | $3.67 | $75k | 7,614 | Jan 6, 2026 |
| Jan 6, 2026 | Khurram Jamil Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -21,446 | $3.65 | $78k | 0 | Jan 6, 2026 |
| Jan 6, 2026 | Joel Lewis President and CEO | SOpen-market sale Common Stock10b5-1 | -37,698 | $3.58 | $135k | 832,592 | Jan 6, 2026 |
| Jan 1, 2026 | Jack W Callicutt Chief Financial Officer | MOption exercise Restricted Stock Unitderivative10b5-1 | -60,000 | $0.00 | $0 | 0 | Jan 6, 2026 |
| Jan 1, 2026 | Khurram Jamil Chief Medical Officer | MOption exercise Restricted Stock Unitderivative10b5-1 | -60,000 | $0.00 | $0 | 0 | Jan 6, 2026 |
| Jan 2, 2026 | Joel Lewis President and CEO | MOption exercise Restricted Stock Unitderivative10b5-1 | -84,000 | $0.00 | $0 | 0 | Jan 6, 2026 |
| Dec 31, 2025 | Khurram Jamil Chief Medical Officer | MOption exercise Common Stock10b5-1 | +8,125 | $1.23 | $9,994 | 8,125 | Jan 5, 2026 |
| Dec 31, 2025 | Khurram Jamil Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -8,125 | $4.07 | $33k | 0 | Jan 5, 2026 |
| Dec 31, 2025 | Khurram Jamil Chief Medical Officer | MOption exercise Stock option (right to buy)derivative10b5-1 | -8,125 | $0.00 | $0 | 40,625 | Jan 5, 2026 |
| Dec 23, 2025 | Kary Eldred director | POpen-market purchase Common Stock10b5-1 | +700 | $3.73 | $2,611 | 65,382 | Dec 23, 2025 |
| Dec 23, 2025 | Kary Eldred director | POpen-market purchase Common Stock | +700 | $3.73 | $2,611 | 65,382 | Dec 23, 2025 |
| Dec 23, 2025 | Kevin D Freeman director | POpen-market purchase Common Stock10b5-1 | +5,500 | $3.55 | $20k | 55,269 | Dec 23, 2025 |
| Dec 23, 2025 | Kevin D Freeman director | POpen-market purchase Common Stock10b5-1 | +5,500 | $3.55 | $20k | 55,269 | Dec 23, 2025 |
| Dec 23, 2025 | Kevin D Freeman director | POpen-market purchase Common Stock | +5,500 | $3.55 | $20k | 55,269 | Dec 23, 2025 |
| Dec 17, 2025 | Harold H. Shlevin director | MOption exercise Common Stock10b5-1 | +20,000 | $1.98 | $40k | 31,206 | Dec 19, 2025 |
| Dec 17, 2025 | Joel Lewis President and CEO | MOption exercise Common Stock10b5-1 | +7,829 | $2.86 | $22k | 840,421 | Dec 19, 2025 |
| Dec 17, 2025 | Khurram Jamil Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -4,479 | $7.04 | $32k | 0 | Dec 19, 2025 |
| Dec 17, 2025 | Harold H. Shlevin director | SOpen-market sale Common Stock10b5-1 | -19,793 | $7.04 | $139k | 11,206 | Dec 19, 2025 |
| Dec 17, 2025 | Joel Lewis President and CEO | SOpen-market sale Common Stock10b5-1 | -7,829 | $7.06 | $55k | 832,592 | Dec 19, 2025 |
| Dec 17, 2025 | Khurram Jamil Chief Medical Officer | MOption exercise Common Stock10b5-1 | +6,463 | $2.20 | $14k | 6,463 | Dec 19, 2025 |
| Dec 17, 2025 | Harold H. Shlevin director | SOpen-market sale Common Stock10b5-1 | -4,706 | $7.04 | $33k | 6,500 | Dec 19, 2025 |
50 of 235 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- 10X Fund, L.P.owner
- Gilbert F Ameliodirector
- Henry Bremdirector
- Jack W CallicuttChief Financial Officer
- Benjamin Carson Srdirector
- Kary Eldreddirector
- Kevin D Freemandirector
- Khurram JamilChief Medical Officer
- Joel LewisPresident and CEO
- Gilbert S Omenndirector
- Elissa J. Schwartzdirector
- Harold H. Shlevindirector
- Richard E Uihleindirector, owner
- Richard A. Zordani Jr.director
Questions about GALT
Answered from the filings on this page, as of the latest one.
Are insiders buying GALT?
No. In the last 90 days no insider at GALECTIN THERAPEUTICS INC bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade GALT on the open market?
Kary Eldred (director) bought $810 of GALT on Feb 6, 2026 and filed the Form 4 on Feb 9, 2026. InsiderTell scored 23 (weak).
How many insiders file Form 4 at GALECTIN THERAPEUTICS INC?
14 people have filed a Form 4 at GALECTIN THERAPEUTICS INC, among them 10X Fund, L.P. (10% owner), Gilbert F Amelio (director), Henry Brem (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.